🚀 VC round data is live in beta, check it out!
Opus Genetics Valuation Multiples
Discover revenue and EBITDA valuation multiples for Opus Genetics and similar public comparables like Ever Supreme Bio Technology, Newron Pharmaceuticals, Autolus Therapeutics, PureTech Health and more.
Opus Genetics Overview
About Opus Genetics
Opus Genetics Inc is a clinical-stage ophthalmic biopharmaceutical company developing therapies to treat patients with inherited retinal diseases (IRDs) and therapies to treat patients with other retinal and refractive disorders. The pipeline includes adeno-associated virus (AAV)-based gene therapies that address mutations in genes that cause different forms of bestrophinopathy, Leber congenital amaurosis (LCA), and retinitis pigmentosa. The pipeline also includes Phentolamine Ophthalmic Solution 0.75%, a non-selective alpha-1 and alpha-2 adrenergic antagonist to reduce pupil size, and APX3330, a novel small-molecule inhibitor of Ref-1 to slow the progression of non-proliferative diabetic retinopathy.
Founded
2018
HQ
Employees
18
Website
Sectors
Financials (LTM)
EV
$347M
Opus Genetics Financials
Opus Genetics reported last 12-month revenue of $15M.
In the same LTM period, Opus Genetics generated $15M in gross profit and had net loss of ($49M).
Revenue (LTM)
Opus Genetics P&L
In the most recent fiscal year, Opus Genetics reported revenue of $14M and EBITDA of ($48M).
Opus Genetics expects next 12-month revenue of XXX and NTM EBITDA of XXX
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue | $15M | XXX | $14M | XXX | XXX | XXX |
| Gross Profit | $15M | XXX | — | XXX | XXX | XXX |
| Gross Margin | 100% | XXX | — | XXX | XXX | XXX |
| EBITDA | — | XXX | ($48M) | XXX | XXX | XXX |
| EBITDA Margin | — | XXX | (339%) | XXX | XXX | XXX |
| EBIT Margin | (279%) | XXX | (272%) | XXX | XXX | XXX |
| Net Profit | ($49M) | XXX | ($50M) | XXX | XXX | XXX |
| Net Margin | (334%) | XXX | (349%) | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
Opus Genetics Stock Performance
Opus Genetics has current market cap of $391M, and enterprise value of $347M.
Market Cap Evolution
Opus Genetics' stock price is $5.50.
| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $347M | $391M | 6.6% | XXX | XXX | XXX | $-0.70 |
Benchmark Trading Valuation Multiples by Industry
Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.
Start Free TrialOpus Genetics Valuation Multiples
Opus Genetics trades at 23.6x EV/Revenue multiple, and (7.2x) EV/EBITDA.
EV / Revenue (LTM)
Opus Genetics Financial Valuation Multiples
As of April 11, 2026, Opus Genetics has market cap of $391M and EV of $347M.
Equity research analysts estimate Opus Genetics' 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Opus Genetics has a P/E ratio of (7.9x).
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $391M | XXX | $391M | XXX | XXX | XXX |
| EV (current) | $347M | XXX | $347M | XXX | XXX | XXX |
| EV/Revenue | 23.6x | XXX | 24.4x | XXX | XXX | XXX |
| EV/EBITDA | — | XXX | (7.2x) | XXX | XXX | XXX |
| EV/EBIT | (8.4x) | XXX | (9.0x) | XXX | XXX | XXX |
| EV/Gross Profit | 23.6x | XXX | — | XXX | XXX | XXX |
| P/E | (7.9x) | XXX | (7.9x) | XXX | XXX | XXX |
| EV/FCF | — | XXX | (9.8x) | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Verified Opus Genetics Valuation Multiples
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.
Opus Genetics Margins & Growth Rates
Opus Genetics' revenue in the last 12 month grew by 11%.
Opus Genetics' revenue per employee in the last FY averaged $0.8M, while opex per employee averaged $2.9M for the same period.
Opus Genetics Operational Valuation Multiples
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 11% | XXX | 13% | XXX | XXX | XXX |
| EBITDA Margin | — | XXX | (339%) | XXX | XXX | XXX |
| EBITDA Growth | — | XXX | (16%) | XXX | XXX | XXX |
| Revenue per Employee | — | XXX | $0.8M | XXX | XXX | XXX |
| Opex per Employee | — | XXX | $2.9M | XXX | XXX | XXX |
| G&A Expenses to Revenue | 150% | XXX | 155% | XXX | XXX | XXX |
| R&D Expenses to Revenue | 233% | XXX | 217% | XXX | XXX | XXX |
| Opex to Revenue | — | XXX | 372% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Opus Genetics Public Comps
See public comps and valuation multiples for other Biopharmaceuticals comps.
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| LTM | 2026E | 2027E | LTM | 2026E | 2027E | |
| Ever Supreme Bio Technology | XXX | XXX | XXX | XXX | XXX | XXX |
| Newron Pharmaceuticals | XXX | XXX | XXX | XXX | XXX | XXX |
| Autolus Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| PureTech Health | XXX | XXX | XXX | XXX | XXX | XXX |
| CytoDyn | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Opus Genetics M&A Activity
Opus Genetics acquired XXX companies to date.
Last acquisition by Opus Genetics was on XXXXXXXX, XXXXX. Opus Genetics acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Acquisitions by Opus Genetics
| Acquired Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Get Verified M&A Valuation Multiples
Sign up to see revenue and EBITDA valuation multiples for 150K+ M&A deals.
Start Free TrialOpus Genetics Investment Activity
Opus Genetics invested in XXX companies to date.
Opus Genetics made its latest investment on XXXXXXXX, XXXXX. Opus Genetics invested in XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Investments by Opus Genetics
| Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialAbout Opus Genetics
| When was Opus Genetics founded? | Opus Genetics was founded in 2018. |
| Where is Opus Genetics headquartered? | Opus Genetics is headquartered in United States. |
| How many employees does Opus Genetics have? | As of today, Opus Genetics has over 18 employees. |
| Who is the CEO of Opus Genetics? | Opus Genetics' CEO is George Magrath. |
| Is Opus Genetics publicly listed? | Yes, Opus Genetics is a public company listed on Nasdaq. |
| What is the stock symbol of Opus Genetics? | Opus Genetics trades under IRD ticker. |
| When did Opus Genetics go public? | Opus Genetics went public in 2020. |
| Who are competitors of Opus Genetics? | Opus Genetics main competitors are Ever Supreme Bio Technology, Newron Pharmaceuticals, Autolus Therapeutics, PureTech Health. |
| What is the current market cap of Opus Genetics? | Opus Genetics' current market cap is $391M. |
| What is the current revenue of Opus Genetics? | Opus Genetics' last 12 months revenue is $15M. |
| What is the current revenue growth of Opus Genetics? | Opus Genetics revenue growth (NTM/LTM) is 11%. |
| What is the current EV/Revenue multiple of Opus Genetics? | Current revenue multiple of Opus Genetics is 23.6x. |
| Is Opus Genetics profitable? | No, Opus Genetics is not profitable. |
| What is the current net income of Opus Genetics? | Opus Genetics' last 12 months net income is ($49M). |
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.